← All trials
NCT05938296
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Jan 1, 2026
- First posted
- Jul 10, 2023
- Last posted
- Dec 26, 2023
- Enrollment
- 29
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Binhui Biopharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.